Related Experiment Video
Updated: Jun 5, 2025
14:57
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
14.4K
[SGLT2 inhibitors : promises, but for whom ?]
Camille Lanfranchi1, Pierre-Alain Jolivot1, Joël Wermeille1
1Pharmacie interjurassienne, Hôpitaux et institutions de soins du canton du Jura, du Jura bernois et du canton de Neuchâtel, 2740 Moutier.
Revue Medicale Suisse
|December 6, 2024
Summary
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) offer benefits for heart failure hospitalizations and kidney function in type 2 diabetes. However, their modest physiological impact and significant side effects warrant careful patient selection.
Area of Science:
- Endocrinology
- Cardiology
- Nephrology
Context:
- Type 2 diabetes management involves emerging therapeutic classes like sodium-glucose cotransporter-2 inhibitors (SGLT2i).
- Pivotal studies highlight SGLT2i's potential benefits in cardiovascular and renal outcomes.
Purpose:
- To critically evaluate the interpretation of clinical studies on SGLT2i.
- To identify patient populations where the benefit/risk balance of SGLT2i may not be favorable.
Summary:
- SGLT2i demonstrate efficacy in reducing heart failure hospitalizations and slowing renal function decline in type 2 diabetes.
- The impact on weight, glycated hemoglobin, and blood pressure is modest.
- Adverse effects, including urogenital infections and ketoacidosis, are notable, particularly in the elderly.
Impact:
- Clinical interpretation of SGLT2i efficacy requires careful consideration of both benefits and risks.
- Identifying specific patient subgroups who may not benefit or could experience harm is crucial for optimizing SGLT2i therapy.
- This critical appraisal aims to guide more judicious use of SGLT2i in type 2 diabetes management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K